Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Treatment pathways for patients with triple-negative breast cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 23.10.19
Views: 562

Elahe Salehi - Dana-Farber Cancer Institute, Boston, USA

Elahe Salehi speaks to ecancer at the APAO 2019 meeting in Boston about the treatment pathways used at The Dana-Farber Cancer Institute for patients with triple-negative breast cancer.

She references the results of the IMpassion130 clinical trial and the use of atezolizumab in combination with nab-paclitaxel is the standard of care used at the Dana-Farber Cancer Institute for their metastatic patients.

Salehi discusses the adverse events associated with immunotherapy which can result in a delay in therapy.

Related videos

follow us

Donate to ecancer

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation